<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Clinical trials on FinanClub</title>
    <link>https://finan.club/tags/clinical-trials/</link>
    <description>Recent content in Clinical trials on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Mon, 15 Jan 2024 09:02:23 +0000</lastBuildDate><atom:link href="https://finan.club/tags/clinical-trials/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>IMGN</title>
      <link>https://finan.club/us/imgn/</link>
      <pubDate>Mon, 15 Jan 2024 09:02:23 +0000</pubDate>
      
      <guid>https://finan.club/us/imgn/</guid>
      <description>score:162
Chances: ImmunoGen (IMGN) has seen solid earnings estimate revision activity over the past two months. ImmunoGen might move higher on growing optimism about its earnings prospects. ImmunoGen and other stocks have been added to the Zacks Rank #1 (Strong Buy) List. ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).</description>
    </item>
    
    <item>
      <title>TGTX</title>
      <link>https://finan.club/us/tgtx/</link>
      <pubDate>Wed, 10 Jan 2024 09:03:07 +0000</pubDate>
      
      <guid>https://finan.club/us/tgtx/</guid>
      <description>score:343
Chances: TG Therapeutics, Inc. has entered into an agreement to acquire a worldwide license to Precision BioSciences, Inc.&amp;rsquo;s Azercabtagene Zapreleucel (azer-cel), an allogeneic CD19 CAR T cell therapy program for autoimmune diseases. The average of price targets set by Wall Street analysts indicates a potential upside of 127.</description>
    </item>
    
    <item>
      <title>ARWR</title>
      <link>https://finan.club/us/arwr/</link>
      <pubDate>Thu, 04 Jan 2024 09:10:03 +0000</pubDate>
      
      <guid>https://finan.club/us/arwr/</guid>
      <description>score:114
Chances: The company has successfully priced an underwritten registered offering, indicating strong investor interest and potential for significant capital influx. The filing of an application for clearance to initiate a Phase 1/2a clinical trial of ARO-CFB demonstrates progress in the companyâ€™s pipeline development.</description>
    </item>
    
  </channel>
</rss>
